In:
Journal of Gastroenterology and Hepatology, Wiley, Vol. 29, No. 7 ( 2014-07), p. 1463-1469
Abstract:
Sorafenib is recommended as a standard treatment for advanced hepatocellular carcinoma ( HCC ). The efficacy and safety of sorafenib as a first‐line therapy in K orean patients with advanced HCC were investigated. Methods From 2007 to 2012, 86 patients with advanced HCC ( B arcelona C linic L iver C ancer stage C ) treated with sorafenib as a first‐line therapy were enrolled from five tertiary hospitals. Predictors of overall survival ( OS ) and progression‐free survival ( PFS ) were analyzed. Results The median age was 59.5 years, and 71 (82.6%) were males; 57 (66.3%) patients were in C hild– P ugh class A . The median OS and PFS were 5.0 (range 4.0–5.9) and 3.2 (range 2.6–3.7) months, respectively. Regarding OS , C hild– P ugh class A (6.0 vs 2.8 months), tumor diameter 〈 5 cm (6.0 vs 4.3 months), baseline α‐fetoprotein 〈 200 ng/m L (5.8 vs 4.1 months), and the advent of hand‐foot‐skin reaction of ≥ grade 2 (5.9 vs 4.0 months) were independent favorable predictors (all P 〈 0.05). Similarly, regarding PFS , C hild– P ugh class A (4.3 vs 2.1 months), tumor diameter 〈 5 cm (3.9 vs 2.8 months), baseline α‐fetoprotein 〈 200 ng/ mL (5.6 vs 2.8 months), and the advent of hand‐foot‐skin reaction of ≥ grade 2 (4.5 vs 2.6 months) were independent favorable predictors (all P 〈 0.05). All toxicities during sorafenib treatment were manageable. Conclusions Because the efficacy of sorafenib seems marginal in K orean patients with treatment‐naïve HCC , how to select candidates with favorable outcomes should be further investigated.
Type of Medium:
Online Resource
ISSN:
0815-9319
,
1440-1746
DOI:
10.1111/jgh.2014.29.issue-7
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
2006782-3
Permalink